Research progress on the roles and inhibitors of deubiquitinase USP28 in tumors

Xing LI; Bo-ya ZHANG; Li-ting LU; Yan WANG; Shuai WEN; Yong-jun ZANG; Xiang-ming XU; Yi MOU

Return

Research progress on the roles and inhibitors of deubiquitinase USP28 in tumors

VernacularTitle:去泛素化酶USP28在肿瘤中的作用及其抑制剂研究进展
Author: Xing LI ^{1
,

2} ; Bo-ya ZHANG ^{1
,

2} ; Li-ting LU ^{1
,

2} ; Yan WANG ^{1
,

2} ; Shuai WEN ^{1
,

2} ; Yong-jun ZANG ³ ; Xiang-ming XU ^{1
,

2} ; Yi MOU ^{1
,

2}
Author Information

1. College of Pharmacy and Chemistry &
2. Chemical Engineering, Taizhou University, Taizhou
3. Department of Biological and Pharmaceutical Engineering, West Anhui University, Lu'an
Publication Type:Research Article
Keywords: eubiquitylating enzyme; ubiquitin-specific protease 28; cancer; inhibitor; ubiquitination
From: Acta Pharmaceutica Sinica 2024;59(11):2941-2952
CountryChina
Language:Chinese
Abstract: The deubiquitinases (DUBs), as the crucial peptidohydrolases in the ubiquitin system, can reverse and strictly regulate ubiquitination and play key roles in various biological processes, including the regulation of protein stability, cell signal transduction. Ubiquitin-specific protease 28 (USP28) involves multiple cancer-related signaling pathways by enhancing the stability of various cancer-related proteins, and is closely associated with the progression of colorectal, breast cancer, lung carcinomas, and pancreatic cancer. USP28 has been considered as a promising drug target in anticancer therapy, and the development of USP28 inhibitors has made some progress. In this article, we review the structure of USP28 and its interaction with substrates, discuss the research progress of USP28 in cancers and summarize the development of USP28 inhibitors.